ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antihypertensive Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-35W1187
Home | Market Reports | Health| Health Conditions| Heart & Hypertension
Global Antihypertensive Market Insights Forecast to 2028
BUY CHAPTERS

Global Antihypertensive Market Research Report 2025

Code: QYRE-Auto-35W1187
Report
August 2025
Pages:114
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Pfizer Inc
Sanofi
Merck
Boehringer Ingelheim
Lupin Ltd
Johnson & Johnson
Daiichi Sankyo
Norvatis
Astrazeneca plc
GSK
Bayer
Bristol–Myers Squibb
Tekeda
Ranbaxy Laboratories
Shihuida Pharm
Second Pharmaceutical
Yangtze River Pharmaceutical
Hengrui Medicine
Qilu Pharmaceutical
HUALON
Dawnrays
HISUN Pharmceutical

Antihypertensive Market Size

The global market for Antihypertensive was valued at US$ 20080 million in the year 2024 and is projected to reach a revised size of US$ 23240 million by 2031, growing at a CAGR of 2.1% during the forecast period.

Antihypertensive Market

Antihypertensive Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Antihypertensive, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihypertensive.
The Antihypertensive market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antihypertensive market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antihypertensive manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Antihypertensive Market Report

Report Metric Details
Report Name Antihypertensive Market
Accounted market size in year US$ 20080 million
Forecasted market size in 2031 US$ 23240 million
CAGR 2.1%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Diuretics
  • Angiotensin Converting Enzyme (ACE) Inhibitors
  • Angiotensin Receptor Blockers (ARBs)
  • Calcium Channel Blockers
  • Beta Blockers
  • Alpha Blockers
  • Vasodilators & Renin Inhibitors
Segment by Application
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Pfizer, Norvatis, Merck & Co., Sanofi, AstraZeneca, GSK, Daiichi-Sankyo, Boehringer-Ingelheim, Bayer, Johnson & Johnson, Bristol-Myers Squibb, Tekeda, Ranbaxy Laboratories, Shihuida Pharm, Second Pharmaceutical, Lupin Limited., Yangtze River Pharmaceutical, Hengrui Medicine, Qilu Pharmaceutical, HUALON, Dawnrays, HISUN Pharmceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Antihypertensive manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Antihypertensive in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Antihypertensive Market growing?

Ans: The Antihypertensive Market witnessing a CAGR of 2.1% during the forecast period 2025-2031.

What is the Antihypertensive Market size in 2031?

Ans: The Antihypertensive Market size in 2031 will be US$ 23240 million.

Who are the main players in the Antihypertensive Market report?

Ans: The main players in the Antihypertensive Market are Pfizer, Norvatis, Merck & Co., Sanofi, AstraZeneca, GSK, Daiichi-Sankyo, Boehringer-Ingelheim, Bayer, Johnson & Johnson, Bristol-Myers Squibb, Tekeda, Ranbaxy Laboratories, Shihuida Pharm, Second Pharmaceutical, Lupin Limited., Yangtze River Pharmaceutical, Hengrui Medicine, Qilu Pharmaceutical, HUALON, Dawnrays, HISUN Pharmceutical

What are the Application segmentation covered in the Antihypertensive Market report?

Ans: The Applications covered in the Antihypertensive Market report are Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others

What are the Type segmentation covered in the Antihypertensive Market report?

Ans: The Types covered in the Antihypertensive Market report are Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Blockers, Alpha Blockers, Vasodilators & Renin Inhibitors

1 Antihypertensive Market Overview
1.1 Product Definition
1.2 Antihypertensive by Type
1.2.1 Global Antihypertensive Market Value Comparison by Type (2024 VS 2031)
1.2.2 Diuretics
1.2.3 Angiotensin Converting Enzyme (ACE) Inhibitors
1.2.4 Angiotensin Receptor Blockers (ARBs)
1.2.5 Calcium Channel Blockers
1.2.6 Beta Blockers
1.2.7 Alpha Blockers
1.2.8 Vasodilators & Renin Inhibitors
1.3 Antihypertensive by Application
1.3.1 Global Antihypertensive Market Value by Application (2024 VS 2031)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Global Antihypertensive Market Size Estimates and Forecasts
1.4.1 Global Antihypertensive Revenue 2020-2031
1.4.2 Global Antihypertensive Sales 2020-2031
1.4.3 Global Antihypertensive Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Antihypertensive Market Competition by Manufacturers
2.1 Global Antihypertensive Sales Market Share by Manufacturers (2020-2025)
2.2 Global Antihypertensive Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Antihypertensive Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Antihypertensive, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antihypertensive, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antihypertensive, Product Type & Application
2.7 Global Key Manufacturers of Antihypertensive, Date of Enter into This Industry
2.8 Global Antihypertensive Market Competitive Situation and Trends
2.8.1 Global Antihypertensive Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Antihypertensive Players Market Share by Revenue
2.8.3 Global Antihypertensive Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antihypertensive Market Scenario by Region
3.1 Global Antihypertensive Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Antihypertensive Sales by Region: 2020-2031
3.2.1 Global Antihypertensive Sales by Region: 2020-2025
3.2.2 Global Antihypertensive Sales by Region: 2026-2031
3.3 Global Antihypertensive Revenue by Region: 2020-2031
3.3.1 Global Antihypertensive Revenue by Region: 2020-2025
3.3.2 Global Antihypertensive Revenue by Region: 2026-2031
3.4 North America Antihypertensive Market Facts & Figures by Country
3.4.1 North America Antihypertensive Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Antihypertensive Sales by Country (2020-2031)
3.4.3 North America Antihypertensive Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Antihypertensive Market Facts & Figures by Country
3.5.1 Europe Antihypertensive Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Antihypertensive Sales by Country (2020-2031)
3.5.3 Europe Antihypertensive Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antihypertensive Market Facts & Figures by Region
3.6.1 Asia Pacific Antihypertensive Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Antihypertensive Sales by Region (2020-2031)
3.6.3 Asia Pacific Antihypertensive Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Antihypertensive Market Facts & Figures by Country
3.7.1 Latin America Antihypertensive Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Antihypertensive Sales by Country (2020-2031)
3.7.3 Latin America Antihypertensive Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antihypertensive Market Facts & Figures by Country
3.8.1 Middle East and Africa Antihypertensive Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Antihypertensive Sales by Country (2020-2031)
3.8.3 Middle East and Africa Antihypertensive Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Antihypertensive Sales by Type (2020-2031)
4.1.1 Global Antihypertensive Sales by Type (2020-2025)
4.1.2 Global Antihypertensive Sales by Type (2026-2031)
4.1.3 Global Antihypertensive Sales Market Share by Type (2020-2031)
4.2 Global Antihypertensive Revenue by Type (2020-2031)
4.2.1 Global Antihypertensive Revenue by Type (2020-2025)
4.2.2 Global Antihypertensive Revenue by Type (2026-2031)
4.2.3 Global Antihypertensive Revenue Market Share by Type (2020-2031)
4.3 Global Antihypertensive Price by Type (2020-2031)
5 Segment by Application
5.1 Global Antihypertensive Sales by Application (2020-2031)
5.1.1 Global Antihypertensive Sales by Application (2020-2025)
5.1.2 Global Antihypertensive Sales by Application (2026-2031)
5.1.3 Global Antihypertensive Sales Market Share by Application (2020-2031)
5.2 Global Antihypertensive Revenue by Application (2020-2031)
5.2.1 Global Antihypertensive Revenue by Application (2020-2025)
5.2.2 Global Antihypertensive Revenue by Application (2026-2031)
5.2.3 Global Antihypertensive Revenue Market Share by Application (2020-2031)
5.3 Global Antihypertensive Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Pfizer Antihypertensive Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Norvatis
6.2.1 Norvatis Company Information
6.2.2 Norvatis Description and Business Overview
6.2.3 Norvatis Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Norvatis Antihypertensive Product Portfolio
6.2.5 Norvatis Recent Developments/Updates
6.3 Merck & Co.
6.3.1 Merck & Co. Company Information
6.3.2 Merck & Co. Description and Business Overview
6.3.3 Merck & Co. Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Merck & Co. Antihypertensive Product Portfolio
6.3.5 Merck & Co. Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Company Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Sanofi Antihypertensive Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Company Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.5.4 AstraZeneca Antihypertensive Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 GSK
6.6.1 GSK Company Information
6.6.2 GSK Description and Business Overview
6.6.3 GSK Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.6.4 GSK Antihypertensive Product Portfolio
6.6.5 GSK Recent Developments/Updates
6.7 Daiichi-Sankyo
6.7.1 Daiichi-Sankyo Company Information
6.7.2 Daiichi-Sankyo Description and Business Overview
6.7.3 Daiichi-Sankyo Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Daiichi-Sankyo Antihypertensive Product Portfolio
6.7.5 Daiichi-Sankyo Recent Developments/Updates
6.8 Boehringer-Ingelheim
6.8.1 Boehringer-Ingelheim Company Information
6.8.2 Boehringer-Ingelheim Description and Business Overview
6.8.3 Boehringer-Ingelheim Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Boehringer-Ingelheim Antihypertensive Product Portfolio
6.8.5 Boehringer-Ingelheim Recent Developments/Updates
6.9 Bayer
6.9.1 Bayer Company Information
6.9.2 Bayer Description and Business Overview
6.9.3 Bayer Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Bayer Antihypertensive Product Portfolio
6.9.5 Bayer Recent Developments/Updates
6.10 Johnson & Johnson
6.10.1 Johnson & Johnson Company Information
6.10.2 Johnson & Johnson Description and Business Overview
6.10.3 Johnson & Johnson Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Johnson & Johnson Antihypertensive Product Portfolio
6.10.5 Johnson & Johnson Recent Developments/Updates
6.11 Bristol-Myers Squibb
6.11.1 Bristol-Myers Squibb Company Information
6.11.2 Bristol-Myers Squibb Description and Business Overview
6.11.3 Bristol-Myers Squibb Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Bristol-Myers Squibb Antihypertensive Product Portfolio
6.11.5 Bristol-Myers Squibb Recent Developments/Updates
6.12 Tekeda
6.12.1 Tekeda Company Information
6.12.2 Tekeda Description and Business Overview
6.12.3 Tekeda Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Tekeda Antihypertensive Product Portfolio
6.12.5 Tekeda Recent Developments/Updates
6.13 Ranbaxy Laboratories
6.13.1 Ranbaxy Laboratories Company Information
6.13.2 Ranbaxy Laboratories Description and Business Overview
6.13.3 Ranbaxy Laboratories Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Ranbaxy Laboratories Antihypertensive Product Portfolio
6.13.5 Ranbaxy Laboratories Recent Developments/Updates
6.14 Shihuida Pharm
6.14.1 Shihuida Pharm Company Information
6.14.2 Shihuida Pharm Description and Business Overview
6.14.3 Shihuida Pharm Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Shihuida Pharm Antihypertensive Product Portfolio
6.14.5 Shihuida Pharm Recent Developments/Updates
6.15 Second Pharmaceutical
6.15.1 Second Pharmaceutical Company Information
6.15.2 Second Pharmaceutical Description and Business Overview
6.15.3 Second Pharmaceutical Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Second Pharmaceutical Antihypertensive Product Portfolio
6.15.5 Second Pharmaceutical Recent Developments/Updates
6.16 Lupin Limited.
6.16.1 Lupin Limited. Company Information
6.16.2 Lupin Limited. Description and Business Overview
6.16.3 Lupin Limited. Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Lupin Limited. Antihypertensive Product Portfolio
6.16.5 Lupin Limited. Recent Developments/Updates
6.17 Yangtze River Pharmaceutical
6.17.1 Yangtze River Pharmaceutical Company Information
6.17.2 Yangtze River Pharmaceutical Description and Business Overview
6.17.3 Yangtze River Pharmaceutical Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Yangtze River Pharmaceutical Antihypertensive Product Portfolio
6.17.5 Yangtze River Pharmaceutical Recent Developments/Updates
6.18 Hengrui Medicine
6.18.1 Hengrui Medicine Company Information
6.18.2 Hengrui Medicine Description and Business Overview
6.18.3 Hengrui Medicine Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Hengrui Medicine Antihypertensive Product Portfolio
6.18.5 Hengrui Medicine Recent Developments/Updates
6.19 Qilu Pharmaceutical
6.19.1 Qilu Pharmaceutical Company Information
6.19.2 Qilu Pharmaceutical Description and Business Overview
6.19.3 Qilu Pharmaceutical Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Qilu Pharmaceutical Antihypertensive Product Portfolio
6.19.5 Qilu Pharmaceutical Recent Developments/Updates
6.20 HUALON
6.20.1 HUALON Company Information
6.20.2 HUALON Description and Business Overview
6.20.3 HUALON Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.20.4 HUALON Antihypertensive Product Portfolio
6.20.5 HUALON Recent Developments/Updates
6.21 Dawnrays
6.21.1 Dawnrays Company Information
6.21.2 Dawnrays Description and Business Overview
6.21.3 Dawnrays Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Dawnrays Antihypertensive Product Portfolio
6.21.5 Dawnrays Recent Developments/Updates
6.22 HISUN Pharmceutical
6.22.1 HISUN Pharmceutical Company Information
6.22.2 HISUN Pharmceutical Description and Business Overview
6.22.3 HISUN Pharmceutical Antihypertensive Sales, Revenue and Gross Margin (2020-2025)
6.22.4 HISUN Pharmceutical Antihypertensive Product Portfolio
6.22.5 HISUN Pharmceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antihypertensive Industry Chain Analysis
7.2 Antihypertensive Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antihypertensive Production Mode & Process Analysis
7.4 Antihypertensive Sales and Marketing
7.4.1 Antihypertensive Sales Channels
7.4.2 Antihypertensive Distributors
7.5 Antihypertensive Customer Analysis
8 Antihypertensive Market Dynamics
8.1 Antihypertensive Industry Trends
8.2 Antihypertensive Market Drivers
8.3 Antihypertensive Market Challenges
8.4 Antihypertensive Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Pfizer Inc
Sanofi
Merck
Boehringer Ingelheim
Lupin Ltd
Johnson & Johnson
Daiichi Sankyo
Norvatis
Astrazeneca plc
GSK
Bayer
Bristol–Myers Squibb
Tekeda
Ranbaxy Laboratories
Shihuida Pharm
Second Pharmaceutical
Yangtze River Pharmaceutical
Hengrui Medicine
Qilu Pharmaceutical
HUALON
Dawnrays
HISUN Pharmceutical
List of Tables
 Table 1. Global Antihypertensive Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Antihypertensive Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Antihypertensive Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Antihypertensive Sales (Units) of Key Manufacturers (2020-2025)
 Table 5. Global Antihypertensive Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Antihypertensive Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Antihypertensive Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Antihypertensive Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Antihypertensive, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Antihypertensive, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Antihypertensive, Product Type & Application
 Table 12. Global Key Manufacturers of Antihypertensive, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Antihypertensive by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihypertensive as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Antihypertensive Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Antihypertensive Sales by Region (2020-2025) & (Units)
 Table 18. Global Antihypertensive Sales Market Share by Region (2020-2025)
 Table 19. Global Antihypertensive Sales by Region (2026-2031) & (Units)
 Table 20. Global Antihypertensive Sales Market Share by Region (2026-2031)
 Table 21. Global Antihypertensive Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Antihypertensive Revenue Market Share by Region (2020-2025)
 Table 23. Global Antihypertensive Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Antihypertensive Revenue Market Share by Region (2026-2031)
 Table 25. North America Antihypertensive Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Antihypertensive Sales by Country (2020-2025) & (Units)
 Table 27. North America Antihypertensive Sales by Country (2026-2031) & (Units)
 Table 28. North America Antihypertensive Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Antihypertensive Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Antihypertensive Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Antihypertensive Sales by Country (2020-2025) & (Units)
 Table 32. Europe Antihypertensive Sales by Country (2026-2031) & (Units)
 Table 33. Europe Antihypertensive Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Antihypertensive Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Antihypertensive Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Antihypertensive Sales by Region (2020-2025) & (Units)
 Table 37. Asia Pacific Antihypertensive Sales by Region (2026-2031) & (Units)
 Table 38. Asia Pacific Antihypertensive Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Antihypertensive Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Antihypertensive Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Antihypertensive Sales by Country (2020-2025) & (Units)
 Table 42. Latin America Antihypertensive Sales by Country (2026-2031) & (Units)
 Table 43. Latin America Antihypertensive Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Antihypertensive Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Antihypertensive Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Antihypertensive Sales by Country (2020-2025) & (Units)
 Table 47. Middle East and Africa Antihypertensive Sales by Country (2026-2031) & (Units)
 Table 48. Middle East and Africa Antihypertensive Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Antihypertensive Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Antihypertensive Sales (Units) by Type (2020-2025)
 Table 51. Global Antihypertensive Sales (Units) by Type (2026-2031)
 Table 52. Global Antihypertensive Sales Market Share by Type (2020-2025)
 Table 53. Global Antihypertensive Sales Market Share by Type (2026-2031)
 Table 54. Global Antihypertensive Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Antihypertensive Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Antihypertensive Revenue Market Share by Type (2020-2025)
 Table 57. Global Antihypertensive Revenue Market Share by Type (2026-2031)
 Table 58. Global Antihypertensive Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Antihypertensive Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Antihypertensive Sales (Units) by Application (2020-2025)
 Table 61. Global Antihypertensive Sales (Units) by Application (2026-2031)
 Table 62. Global Antihypertensive Sales Market Share by Application (2020-2025)
 Table 63. Global Antihypertensive Sales Market Share by Application (2026-2031)
 Table 64. Global Antihypertensive Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Antihypertensive Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Antihypertensive Revenue Market Share by Application (2020-2025)
 Table 67. Global Antihypertensive Revenue Market Share by Application (2026-2031)
 Table 68. Global Antihypertensive Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Antihypertensive Price (USD/Unit) by Application (2026-2031)
 Table 70. Pfizer Company Information
 Table 71. Pfizer Description and Business Overview
 Table 72. Pfizer Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Pfizer Antihypertensive Product
 Table 74. Pfizer Recent Developments/Updates
 Table 75. Norvatis Company Information
 Table 76. Norvatis Description and Business Overview
 Table 77. Norvatis Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Norvatis Antihypertensive Product
 Table 79. Norvatis Recent Developments/Updates
 Table 80. Merck & Co. Company Information
 Table 81. Merck & Co. Description and Business Overview
 Table 82. Merck & Co. Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Merck & Co. Antihypertensive Product
 Table 84. Merck & Co. Recent Developments/Updates
 Table 85. Sanofi Company Information
 Table 86. Sanofi Description and Business Overview
 Table 87. Sanofi Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Sanofi Antihypertensive Product
 Table 89. Sanofi Recent Developments/Updates
 Table 90. AstraZeneca Company Information
 Table 91. AstraZeneca Description and Business Overview
 Table 92. AstraZeneca Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. AstraZeneca Antihypertensive Product
 Table 94. AstraZeneca Recent Developments/Updates
 Table 95. GSK Company Information
 Table 96. GSK Description and Business Overview
 Table 97. GSK Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. GSK Antihypertensive Product
 Table 99. GSK Recent Developments/Updates
 Table 100. Daiichi-Sankyo Company Information
 Table 101. Daiichi-Sankyo Description and Business Overview
 Table 102. Daiichi-Sankyo Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Daiichi-Sankyo Antihypertensive Product
 Table 104. Daiichi-Sankyo Recent Developments/Updates
 Table 105. Boehringer-Ingelheim Company Information
 Table 106. Boehringer-Ingelheim Description and Business Overview
 Table 107. Boehringer-Ingelheim Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Boehringer-Ingelheim Antihypertensive Product
 Table 109. Boehringer-Ingelheim Recent Developments/Updates
 Table 110. Bayer Company Information
 Table 111. Bayer Description and Business Overview
 Table 112. Bayer Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. Bayer Antihypertensive Product
 Table 114. Bayer Recent Developments/Updates
 Table 115. Johnson & Johnson Company Information
 Table 116. Johnson & Johnson Description and Business Overview
 Table 117. Johnson & Johnson Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. Johnson & Johnson Antihypertensive Product
 Table 119. Johnson & Johnson Recent Developments/Updates
 Table 120. Bristol-Myers Squibb Company Information
 Table 121. Bristol-Myers Squibb Description and Business Overview
 Table 122. Bristol-Myers Squibb Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 123. Bristol-Myers Squibb Antihypertensive Product
 Table 124. Bristol-Myers Squibb Recent Developments/Updates
 Table 125. Tekeda Company Information
 Table 126. Tekeda Description and Business Overview
 Table 127. Tekeda Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 128. Tekeda Antihypertensive Product
 Table 129. Tekeda Recent Developments/Updates
 Table 130. Ranbaxy Laboratories Company Information
 Table 131. Ranbaxy Laboratories Description and Business Overview
 Table 132. Ranbaxy Laboratories Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 133. Ranbaxy Laboratories Antihypertensive Product
 Table 134. Ranbaxy Laboratories Recent Developments/Updates
 Table 135. Shihuida Pharm Company Information
 Table 136. Shihuida Pharm Description and Business Overview
 Table 137. Shihuida Pharm Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 138. Shihuida Pharm Antihypertensive Product
 Table 139. Shihuida Pharm Recent Developments/Updates
 Table 140. Second Pharmaceutical Company Information
 Table 141. Second Pharmaceutical Description and Business Overview
 Table 142. Second Pharmaceutical Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 143. Second Pharmaceutical Antihypertensive Product
 Table 144. Second Pharmaceutical Recent Developments/Updates
 Table 145. Lupin Limited. Company Information
 Table 146. Lupin Limited. Description and Business Overview
 Table 147. Lupin Limited. Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 148. Lupin Limited. Antihypertensive Product
 Table 149. Lupin Limited. Recent Developments/Updates
 Table 150. Yangtze River Pharmaceutical Company Information
 Table 151. Yangtze River Pharmaceutical Description and Business Overview
 Table 152. Yangtze River Pharmaceutical Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 153. Yangtze River Pharmaceutical Antihypertensive Product
 Table 154. Yangtze River Pharmaceutical Recent Developments/Updates
 Table 155. Hengrui Medicine Company Information
 Table 156. Hengrui Medicine Description and Business Overview
 Table 157. Hengrui Medicine Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 158. Hengrui Medicine Antihypertensive Product
 Table 159. Hengrui Medicine Recent Developments/Updates
 Table 160. Qilu Pharmaceutical Company Information
 Table 161. Qilu Pharmaceutical Description and Business Overview
 Table 162. Qilu Pharmaceutical Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 163. Qilu Pharmaceutical Antihypertensive Product
 Table 164. Qilu Pharmaceutical Recent Developments/Updates
 Table 165. HUALON Company Information
 Table 166. HUALON Description and Business Overview
 Table 167. HUALON Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 168. HUALON Antihypertensive Product
 Table 169. HUALON Recent Developments/Updates
 Table 170. Dawnrays Company Information
 Table 171. Dawnrays Description and Business Overview
 Table 172. Dawnrays Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 173. Dawnrays Antihypertensive Product
 Table 174. Dawnrays Recent Developments/Updates
 Table 175. HISUN Pharmceutical Company Information
 Table 176. HISUN Pharmceutical Description and Business Overview
 Table 177. HISUN Pharmceutical Antihypertensive Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 178. HISUN Pharmceutical Antihypertensive Product
 Table 179. HISUN Pharmceutical Recent Developments/Updates
 Table 180. Key Raw Materials Lists
 Table 181. Raw Materials Key Suppliers Lists
 Table 182. Antihypertensive Distributors List
 Table 183. Antihypertensive Customers List
 Table 184. Antihypertensive Market Trends
 Table 185. Antihypertensive Market Drivers
 Table 186. Antihypertensive Market Challenges
 Table 187. Antihypertensive Market Restraints
 Table 188. Research Programs/Design for This Report
 Table 189. Key Data Information from Secondary Sources
 Table 190. Key Data Information from Primary Sources
 Table 191. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Antihypertensive
 Figure 2. Global Antihypertensive Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Antihypertensive Market Share by Type: 2024 & 2031
 Figure 4. Diuretics Product Picture
 Figure 5. Angiotensin Converting Enzyme (ACE) Inhibitors Product Picture
 Figure 6. Angiotensin Receptor Blockers (ARBs) Product Picture
 Figure 7. Calcium Channel Blockers Product Picture
 Figure 8. Beta Blockers Product Picture
 Figure 9. Alpha Blockers Product Picture
 Figure 10. Vasodilators & Renin Inhibitors Product Picture
 Figure 11. Global Antihypertensive Market Value by Application (2020-2031) & (US$ Million)
 Figure 12. Global Antihypertensive Market Share by Application: 2024 & 2031
 Figure 13. Hospital Pharmacy
 Figure 14. Retail Pharmacy
 Figure 15. Online Pharmacy
 Figure 16. Others
 Figure 17. Global Antihypertensive Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 18. Global Antihypertensive Market Size (2020-2031) & (US$ Million)
 Figure 19. Global Antihypertensive Sales (2020-2031) & (Units)
 Figure 20. Global Antihypertensive Average Price (USD/Unit) & (2020-2031)
 Figure 21. Antihypertensive Report Years Considered
 Figure 22. Antihypertensive Sales Share by Manufacturers in 2024
 Figure 23. Global Antihypertensive Revenue Share by Manufacturers in 2024
 Figure 24. Global 5 and 10 Largest Antihypertensive Players: Market Share by Revenue in Antihypertensive in 2024
 Figure 25. Antihypertensive Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 26. Global Antihypertensive Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 27. North America Antihypertensive Sales Market Share by Country (2020-2031)
 Figure 28. North America Antihypertensive Revenue Market Share by Country (2020-2031)
 Figure 29. U.S. Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Canada Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Europe Antihypertensive Sales Market Share by Country (2020-2031)
 Figure 32. Europe Antihypertensive Revenue Market Share by Country (2020-2031)
 Figure 33. Germany Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. France Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. U.K. Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Italy Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Russia Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Asia Pacific Antihypertensive Sales Market Share by Region (2020-2031)
 Figure 39. Asia Pacific Antihypertensive Revenue Market Share by Region (2020-2031)
 Figure 40. China Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Japan Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. South Korea Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. India Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Australia Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Taiwan Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Indonesia Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Thailand Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Malaysia Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Philippines Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Latin America Antihypertensive Sales Market Share by Country (2020-2031)
 Figure 51. Latin America Antihypertensive Revenue Market Share by Country (2020-2031)
 Figure 52. Mexico Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Brazil Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Argentina Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Middle East and Africa Antihypertensive Sales Market Share by Country (2020-2031)
 Figure 56. Middle East and Africa Antihypertensive Revenue Market Share by Country (2020-2031)
 Figure 57. Turkey Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Saudi Arabia Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. U.A.E Antihypertensive Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 60. Global Sales Market Share of Antihypertensive by Type (2020-2031)
 Figure 61. Global Revenue Market Share of Antihypertensive by Type (2020-2031)
 Figure 62. Global Antihypertensive Price (USD/Unit) by Type (2020-2031)
 Figure 63. Global Sales Market Share of Antihypertensive by Application (2020-2031)
 Figure 64. Global Revenue Market Share of Antihypertensive by Application (2020-2031)
 Figure 65. Global Antihypertensive Price (USD/Unit) by Application (2020-2031)
 Figure 66. Antihypertensive Value Chain
 Figure 67. Channels of Distribution (Direct Vs Distribution)
 Figure 68. Bottom-up and Top-down Approaches for This Report
 Figure 69. Data Triangulation
 Figure 70. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Coronary Imaging Catheter Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32P14840
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Point-of-care Troponin Testing Instrument Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22I19939
Wed Nov 19 00:00:00 UTC 2025

Add to Cart

Global Troponin Analyzer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-38W19812
Wed Nov 19 00:00:00 UTC 2025

Add to Cart

Global Anticoagulant Medications Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-39V16824
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions